Head of JLABS @ San Diego
As Head of JLABS @ San Diego Sanjay is responsible for setting the strategy and overseeing all operational activities. He joined after leading R&D finance operations for the Janssen Pharmaceuticals R&D CFO. Prior to this role he led early stage R&D divestments in partnership with JBD, JJI & JJDC, leading to a number of successful asset out-licenses and the formation of four new companies: Fusion Pharmaceuticals, Provention Bio (PRVB), Mebias Discovery and Aro Therapeutics. He has also led two internal discovery platform venture startups within Janssen R&D whilst managing overall venture operations.
Prior to Janssen Sanjay was with healthcare venture capital firm Quaker Partners, a fund with $700MM under management. Here he primarily invested in bio-pharmaceuticals and diagnostic/tools, including key deals Durata Therapeutics, Rapid Micro Biosystems and RainDance Technologies. Prior to Quaker Partners Sanjay was with Centocor Johnson & Johnson where he cofounded an internal venture to develop potential cell therapies for retinal diseases. Before joining Centocor he was as an entrepreneur at San Diego-based start-up Morphogen Pharmaceuticals, where he led pre-clinical operations to develop cell therapies for cardiovascular and neurological indications.
Sanjay received his PhD in Pharmacology and MSc In Clinical Pharmacology from The University of Aberdeen, UK and trained at Nottingham Trent University, UK in Applied Biology for his BSc. He completed post-doctoral fellowships at the University of Pittsburgh Medical School and at the Scripps Research Institute. He is the holder of 20 issued US patents and has 20 peer-reviewed publications. He is also a Life Science Kauffman Fellow of Class 14.